INSR(IR)
Sign in to save this workspaceUniProt P06213 · PDB · AlphaFold · Substrate: pEY + Mn · Clone: aa 1011-end
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Ceritinib | 97.8% | 2.2% | 95.44 | 0.618 |
| 2 | Gilteritinib | 95.1% | 4.9% | 88.97 | 0.506 |
| 3 | Brigatinib | 94.0% | 6.0% | 82.96 | 0.513 |
| 4 | Alectinib | 91.1% | 8.9% | 95.49 | 0.651 |
| 5 | Nintedanib | 90.5% | 9.5% | 90.23 | 0.608 |
| 6 | Crizotinib | 89.9% | 10.1% | 91.39 | 0.581 |
| 7 | Neratinib | 81.0% | 19.1% | 93.18 | 0.597 |
| 8 | Repotrectinib | 72.4% | 27.6% | 84.21 | 0.608 |
| 9 | Entrectinib | 72.0% | 28.0% | 93.69 | 0.671 |
| 10 | Sunitinib | 71.7% | 28.3% | 91.73 | 0.524 |
| 11 | Fostamatinib | 70.9% | 29.1% | 96.74 | 0.613 |
| 12 | Pacritinib | 60.6% | 39.4% | 88.64 | 0.452 |
| 13 | Bosutinib | 51.5% | 48.5% | 87.22 | 0.555 |
| 14 | Defactinib | 48.0% | 52.0% | 92.68 | 0.450 |
| 15 | Lorlatinib | 39.0% | 61.0% | 97.24 | 0.694 |
| 16 | Ponatinib | 38.5% | 61.5% | 78.23 | 0.534 |
| 17 | Fedratinib | 37.3% | 62.7% | 96.21 | 0.576 |
| 18 | Osimertinib | 33.9% | 66.1% | 97.24 | 0.733 |
| 19 | Vemurafenib | 32.3% | 67.7% | 96.49 | 0.598 |
| 20 | Cabozantinib | 30.8% | 69.2% | 92.73 | 0.751 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 1.72
- Epithelial log2(TPM+1): 2.29
- Fold change: -0.56
- Status: No significant change
Selectivity landscape vs inhibition on INSR
Each point is one of the 92 approved drugs; color = inhibition % on INSR.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…